Economy/Home · Economy

[Breaking] Samsung Bioepis Signs Development and Commercialization Agreement with Teva for Biosimilars SB41 and SB44

Samsung Bioepis, a subsidiary of Samsung Epis Holdings, has signed an early collaboration agreement with Teva Pharmaceuticals International GmbH to jointly pursue the research, development, and commercialization of 'SB41' (a biosimilar of Fasenra), a treatment for severe eosinophilic asthma, and 'SB

Oseong Kwon
Staff Reporter
5 min read
[Breaking] Samsung Bioepis Signs Development and Commercialization Agreement with Teva for Biosimilars SB41 and SB44
CBC News

Samsung Bioepis, a subsidiary of Samsung Epis Holdings, has signed an early collaboration agreement with Teva Pharmaceuticals International GmbH to jointly pursue the research, development, and commercialization of 'SB41' (a biosimilar of Fasenra), a treatment for severe eosinophilic asthma, and 'SB44' (a biosimilar of Ilaris), a treatment for hereditary periodic fever syndromes. The contract was signed on September 30, 2026.

Division of Roles: Samsung Bioepis to Handle Development and Supply, Teva to Handle Sales in the U.S., Europe, and Canada

Under the agreement, Samsung Bioepis will be responsible for the development, manufacturing, and supply of SB41 and SB44, while Teva will handle sales of the products in the United States, Europe, and Canada.

Through this agreement, Teva also secured options for expanding the future sales territories of SB41 and SB44, as well as additional partnerships involving Samsung Bioepis's biosimilar pipeline. Any additional partnerships will be established through separate contracts.

Contract Value and Duration Undisclosed: Only Minimum Receivable Amount Disclosed

The contract period and value were not disclosed by mutual agreement between the two companies for the purpose of maintaining business confidentiality. According to the regulatory filing, the amount Samsung Bioepis is to receive in the future is at least the smaller of 2.5% of its equity capital of 2.2303 trillion won or 2.5% of its revenue of 1.671965 trillion won, based on the 2025 consolidated financial statements. The deadline for withholding disclosure of the contract amount and period is May 31, 2042.

Conditional Contract: Success in Clinical Trials and Product Approval Is Key

This is a conditional agreement. Samsung Bioepis stated that revenue recognition under the contract may vary depending on the success of clinical trials and product approval. Depending on the contract terms, the agreement could be terminated if research and development is halted by regulatory authorities or if product approval fails.

The company added that the contents of the filing are subject to change depending on business circumstances, and that it will promptly make disclosures if any major changes occur or disclosure obligations arise in the future.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.